Friday, December 22, 2023
India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc, has introduced the Symplicity™ Spyral renal denervation system (RDN) for the treatment of high blood pressure. This minimally invasive therapy focuses on nerves near the kidneys that can become overactive, leading to hypertension. Recently approved by the US Food and Drug Administration (FDA) and Indian regulatory authorities, this system is the result of a decade of clinical research and development.
In India, where approximately 1 in 4 adults suffer from hypertension, this advancement is particularly significant. Hypertension is a major contributor to cardiovascular mortality, increasing the risk of heart attack, stroke, heart failure, and kidney failure. Often asymptomatic, hypertension can go undiagnosed. Raising awareness about this condition is crucial, given its detectable, preventable, and treatable nature. The Symplicity SpyralTM blood pressure procedure has proven clinical efficacy in reducing high blood pressure, thus mitigating serious health risks.
This minimally invasive procedure involves a small incision and the insertion of a thin catheter into the kidney artery after sedation. The catheter is then utilized to regulate the excessive activity of nerves connected to the kidney. Importantly, no implants are left behind as the tube is removed, offering a promising solution for hypertension management.
Source: businesswireindia.com
